aorta, middle infrarenal aorta, and distal aorta bifurcation, and the true lumen ratio was calculated accordingly.
) were referred to our division for recurrent VAP aneurysm (median diameter, 64; range, 58-69) after initial TAAA open repair (median time interval, 6.2 years; range, 4-8 years; Table II ) with a prevalence of 2.2% in our open TAAA series (872 cases with the inclusion technique). Four patients (14%) presented connective tissue disorders, and nine patients (31%) had postdissecting aneurysms. Patients were treated by means of redo open repair (O group) in 14 cases (48.3%; Fig 1) , hybrid repair (H group) in 10 (34.5%; Fig 2) , and endovascular custom-made fenestrated endograft (E group) in 5 (17.2%). Outcomes are reported according to the Society for Vascular Surgery/AASS standards. Patients were evaluated with computed tomography scans in the outpatient clinic at 3, 6, and 12 months and then annually if not otherwise required.
Results: Results are summarized in Table III . Technical success (24 hours) was achieved in all cases with a median procedural time of 250 minutes (O: 220 minutes; H: 255 minutes; E: 320 minutes) and median intraoperative estimated blood loss of 1000 mL (O: 1475 mL; H: 550 mL; E: 400 mL). The 30-day mortality was 13.8% (O: 14.3%; H: 20%; E: 0%). Major (grade 2 and 3) perioperative complications (renal, respiratory, cardiac, or spinal cord) were observed in 51.7% of patients (O: 71.5%; H: 50%; E: 0%). Two patients (6.9%) required a postoperative surgical revision for bleeding (O: 1; H: 1), and in two other patients (6.9%), temporary delayed spinal cord ischemia (grade 1) was observed (H: 1; E: 1). At a mean follow-up of 41.7 6 32 months, the overall survival was 55.2%, with two late aneurysm-related deaths in the hybrid group.
Conclusions: VAP aneurysm occurrence after TAAA repair is rare, and over the years, different techniques have been used to address this complex pathology. Redo open repair is associated with not negligible morbidity and mortality rates, and hybrid repair has proven not to be a possible less invasive alternative and, therefore, has been set aside. Fenestrated endovascular treatment with custom-made device is safe and effective, with promising results and it might be considered as an alternative to standard open repair. Objectives: Published rates of reintervention after endovascular aneurysm repair (EVAR) range from 10% to 30%. We evaluated a single university center's experience with reinterventions in the context of trial and United States Food and Drug Administration (FDA)-approved devices.
Methods: Retrospective data collection was performed for patients who underwent infrarenal EVAR and required reintervention from 2000 to 2016. Trial EVARs included FDA feasibility and pivotal trials. Time-to-event analysis, predictors of mortality and explant, and survival analysis were performed with Cox regression, logistic regression, and Kaplan-Meier methods.
Results: From 2000 to 2016, 1835 EVARs were performed, and 137 patients (116 men; mean age, 72.2 6 10.0 years; 7.5% reintervention rate) underwent reintervention with a mean aneurysm size of 5.9 6 1.2 cm. The median follow-up was 5 years, with an overall survival of 70.1%. Device specific details are outlined in the Table. Most patients (79.5%) underwent two or fewer reinterventions, 20.5% underwent three, and 7.9% underwent four. For all devices, the most common etiology of reintervention was type II endoleak (52.5%), followed by type I endoleak (18.2%), type III endoleak (9.5%), limb kink (7.3%), iliac occlusive disease (5.8%), endotension (1.5%), and other. The Fig compares etiol ogies between trial and FDA-approved devices. The overall mean time to the first reintervention was 2.3 6 2.5 years, and univariate Cox regression identified male gender (hazard ratio, 1.91; 95% confidence interval [CI], 1.17-3.10; P ¼ .010) and age at the time of EVAR (hazard ratio, 1.03; 95% CI, 1.01-1.05; P ¼ .006) as risk factors for time to first reintervention. Among all patients requiring reintervention, the mean number of reinterventions for trial devices was significantly greater than that for FDAapproved devices (2.18 vs 1.65; P ¼ .009). Trial devices requiring reintervention had a nearly three-fold increase in odds for the need for greater than two reinterventions (odds ratio, 2.88; 95% CI, 1.12-7.37; P ¼ .031). Trial device, etiology of reintervention, and type of reintervention were not predictive of the need for explant or mortality, but the number of reinterventions was significantly associated with the need for explant (odds ratio, 1.86; 95% CI, 1.17-2.96; P ¼ .009). EVAR device and the need for explant did not impact mortality.
Conclusions: Despite the rigorous nature of patient enrollment in clinical trials and the development of newer iterations of investigational devices, patients undergoing EVAR with trial devices are more likely to undergo a greater number of reinterventions compared to FDAapproved EVARs. Although mortality and the need for explant were not significantly associated with trial devices, the former finding points to an ethical duty to properly inform patients willing to partake in investigational device trials.
Objectives: Endovascular aneurysm repair (EVAR) has become the standard of care for repair of infrarenal aneurysms. Commercially available endografts are available in proximal diameters up to 36 mm, allowing for proximal seal in necks up to 32 mm. We sought to further investigate clinical outcomes following standard EVAR in patients requiring large main body devices.
Methods: We performed a retrospective review of a prospectively maintained database for all patients undergoing elective EVAR for infrarenal abdominal aortic aneurysms at a single institution from 2001 to 2016. 
